Cartesian Therapeutics (RNAC) Accounts Payables (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Accounts Payables data on file, last reported at $1.6 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.6 million, down 23.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 23.8% YoY), and the FY2025 annual result was $1.3 million, up 347.22% from the prior year.
• Accounts Payables advanced to $1.6 million in Q1 2026 per RNAC's latest filing, from $1.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $3.2 million in Q4 2023 and troughed at $214000.0 in Q3 2022.
• A 5-year average of $1.2 million and a median of $693000.0 in 2022 frame the typical range for Accounts Payables.
• On a YoY basis, Accounts Payables climbed as much as 971.91% in 2024 and fell as far as 90.86% in 2024.
• A 5-year view of Accounts Payables shows it stood at $316000.0 in 2022, then soared by 896.84% to $3.2 million in 2023, then tumbled by 90.86% to $288000.0 in 2024, then soared by 347.22% to $1.3 million in 2025, then gained by 24.07% to $1.6 million in 2026.
• Business Quant data shows RNAC's Accounts Payables at $1.6 million in Q1 2026, $1.3 million in Q4 2025, and $2.2 million in Q3 2025.